Supply of Lorlatinib (DOE)

This tender is for the supply of the pharmaceutical product Lorlatinib, identified by the designation (DOE). Lorlatinib is a targeted therapy medication, typically used in the treatment of specific types of cancer, particularly non-small cell lung cancer (NSCLC) that has certain genetic mutations (e.g., ALK-positive or ROS1-positive). The tender likely seeks to procure a specific quantity of this drug for use within a healthcare system, hospital, or research institution. The description is concise, indicating that the core requirement is the physical delivery of the specified medication. Potential bidders are expected to be pharmaceutical suppliers or distributors capable of meeting the regulatory and logistical requirements for handling and supplying prescription drugs. Further details regarding the required quantity, packaging, delivery timelines, and specific quality standards would typically be found in the full tender documentation. This procurement is essential for ensuring patient access to critical cancer treatments.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.